Procter & Gamble (PG): Cheaper Than Its Five-Year Average
Procter & Gamble trades around $146.39, only 9% above its 52-week low of $135 and 11.2% below its high. That alone is unusual for a stock that spends most of its life trading at a premium for stability. The multiple confirms it: 22.1 times trailing earnings against a five-year average of 25.3, a real gap rather than a rounding difference. Something is pricing this differently than the market usually prices Procter & Gamble. Procter & Gamble’s valuation page updates these multiples daily.
Part of the answer showed up this month in the quant data BeStock tracks: P&G’s score sat in B territory, in the low 70s out of 100, through September 8 to 10, then fell to a D, as low as 15, from September 11 onward, and has only partly recovered to 23 as I write this. That is a sharp drop. Sixteen analysts still rate the stock a collective Buy, 56% of them formally, with zero Sell ratings. A quant model and a room full of human analysts disagreeing this sharply is worth digging into rather than picking a side on faith.
My take: the discount is earned, not a mispricing waiting to close. Gross margin has slipped, net income has stopped growing even as revenue has not, and that combination is exactly the kind of thing a momentum-and-fundamentals score is built to catch before a headline explains it. None of that makes P&G a bad business. It makes it a business currently priced for the slower growth it is actually showing, rather than for the premium stability story that usually surrounds it. Procter & Gamble’s financials page has the quarter-by-quarter detail.
This is not a stock people buy for a story. Nobody owns Procter & Gamble because they expect a product launch to reset the growth rate, the way they might with a chipmaker or a biotech name waiting on a trial readout. They own it because the underlying categories, laundry detergent, diapers, razors, toothpaste, do not go away in a downturn, and because the company has proven for decades that it can push price increases through a portfolio built almost entirely around the number one or number two brand in each category it competes in. That pricing power is the whole mechanism behind years of steady organic growth even in quarters when unit volumes barely move. The current margin slip is the first real test of that mechanism in some time, which is exactly why it deserves more attention than a single quarter’s noise would normally get.
Margin, not revenue, is the real story
Full-year revenue rose from $82.0 billion in fiscal 2023 to $84.0 billion in fiscal 2024 to $84.3 billion in fiscal 2025 to $87.0 billion in fiscal 2026, a steady multi-year climb. Net income did not climb with it: $16.1 billion in the latest period against $16.1 billion a year earlier, essentially flat. Gross margin is the reason why, slipping to 50.2% from 51.2%. A percentage point of gross margin on an $87 billion revenue base is real money, and it did not come back in the operating line either; operating margin sits at 23% and EBIT margin at 24.4%, both healthy in absolute terms but not enough to fully offset what commodity and input costs, or pricing given back to defend share, took out of the gross line. Quarterly revenue grew just 2% year over year to $21.2 billion and was flat sequentially, which tells me this is not a one-quarter blip management can wave off as timing.
Two portfolios under one dividend
P&G’s fiscal 2026 segment mix splits almost evenly by geography: 52% of revenue came from international markets and 48% from the United States, which means currency swings and country-specific pricing regulation matter to this stock in a way a purely domestic staples company would not face. By category, Fabric and Home Care is the largest piece at 35% of revenue, Baby, Feminine and Family Care follows at 23%, Beauty at 18%, Health Care at 14%, and Grooming at 8%. That spread across categories is the classic staples defense against any single product cycle going wrong, and it is also why a company this size moves in inches rather than leaps: no single segment is large enough to single-handedly reaccelerate growth, and none is large enough to sink the whole company either.
The quant score that flipped from B to D
The size of the quant swing is what stands out to me more than the letter grade itself. A score in the low 70s dropping to the mid-teens inside a single week, then only partly recovering, usually reflects a shift in price momentum or estimate revisions rather than a single data error. I would not treat a quant score as a standalone reason to sell a position built around a 70-year dividend record, but I also would not ignore a signal that moved this fast on a stock that rarely moves fast at all. Pairing it against Cisco’s own comeback story, where a boring, slow-moving business also had to prove a turn was real before the market re-rated it, is a useful check: boring stocks can still have inflection points, they are just harder to spot because so little else about the stock is moving.
Seventy years of raises, and counting
P&G raised its quarterly dividend to $1.0885 a share from $1.0568 in April 2026, its 70th consecutive annual increase, according to reporting on the raise from The Motley Fool, which puts the company among only five Dividend Kings with a streak that long. Trailing dividends of $4.26 give a 2.91% yield at the current price, funded by roughly 64% of trailing earnings per share. That payout ratio has room in it even with margin under some pressure, and a 70-year streak is not the kind of thing a management team lets break over one soft year of gross margin. It is the reason a dividend growth investor can look at this discount differently than a pure value investor would: the yield and the raise history are the actual product being sold here, not just a side benefit of buying cheap.
I would put P&G closer to the dividend growth camp than the high-yield camp in how it should be judged. A 2.91% yield will not turn heads next to a 6% payer, but the case for dividend growth over high yield rests on the raise continuing for decades, not on the starting number, and few companies anywhere have a longer proof of that than this one. Investors building an income sleeve around durable payers rather than the highest posted yield would put P&G on the short list almost by default, margin wobble and quant downgrade included, because seventy years of raises is itself a kind of evidence a single soft quarter rarely overturns.
| Metric | PG now | Context |
|---|---|---|
| Trailing P/E | 22.1 | five-year average 25.3 |
| Forward P/E | 20.7 | implies 7% EPS growth |
| Gross margin | 50.2% | down from 51.2% a year earlier |
| Net income | $16.1 billion | vs $16.1 billion a year earlier |
| Quant score | D, 23/100 | was B, low 70s, before September 11 |
| Analyst rating | 56% Buy / 0% Sell | of 16 analysts |
| Dividend, trailing | $4.26 | yield 2.91%, 70th straight annual raise |
What the old private-label worry still tests
Every staples company faces the same seasonal fear: when household budgets tighten, some share of buyers trade down to store brands that undercut on price. It is a real risk, and P&G’s own gross margin slide is at least consistent with it, whether the cause is that trade-down pressure, higher input costs, or price given back deliberately to defend shelf space against it. I cannot separate those three causes cleanly from the numbers alone, and that is the one honest uncertainty in this entire analysis: a percentage point of gross margin can come from any of them, and only the next couple of quarters of category-level detail will say which. What I can say is that revenue kept growing through the same stretch, which argues against a straightforward volume collapse to cheaper alternatives; if private label were winning outright, the top line would likely show it before the margin line did.
Short interest sits at 1.2% of the float, unremarkable and not a signal of any organized bearish thesis against the stock. Nobody with real conviction is betting against P&G here; the disagreement, such as it is, sits entirely between the analyst consensus and BeStock’s own quant model, not between bulls and short sellers.
What sixteen analysts are pricing in
The average price target of $161 implies 10% upside from here, and the high estimate of $179 implies 22%. The low estimate, $148, implies only 1% upside, which in practice means even the most cautious published target does not expect the stock to fall from here. That is a narrower band than the quant score’s sharp drop would suggest, and it is the clearest sign that Wall Street’s fundamental analysts and BeStock’s quant model are reading the same margin data and drawing different conclusions about how much it matters.
Where I land: a holder building a position here on the dividend record and the below-average multiple has a real case, but I would not call 22.1 times earnings cheap enough to ignore why the multiple compressed. The specific number I would watch is gross margin in the next quarterly report, due October 22, 2026: a sequential improvement back toward 51.2% would tell me the pressure is transitory input costs working through the system, while another leg down would say pricing power is finally meeting resistance, the exact risk the private-label question always raised for this stock. Until that print, I would treat the quant downgrade as a real flag rather than noise to explain away.
Analysis and opinion only, not investment advice. Figures come from Procter & Gamble’s filings on SEC EDGAR and its investor site; valuation multiples are approximate and were checked on September 18, 2026.
Sources: Dividends (SEC Investor.gov glossary) (https://www.investor.gov/introduction-investing/investing-basics/glossary/dividend) · Dividends tax topic (IRS) (https://www.irs.gov/taxtopics/tc404)